Now available TYRUKO®

TYRUKO® (natalizumab-sztn) is biosimilar to TYSABRI® (natalizumab). TYRUKO is an integrin receptor antagonist indicated for treatment of:

 

TYRUKO is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsingremitting disease, and active secondary progressive disease, in adults. Natalizumab products increase the risk of PML [see Warnings and Precautions]. When initiating and continuing treatment with TYRUKO, physicians should consider whether the expected benefit of TYRUKO is

sufficient to offset this risk.

 

TYRUKO is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.

 

Important Limitations:

In CD, TYRUKO should not be used in combination with immunosuppressants or inhibitors of TNF-α.

View full prescribing information.